Bronchiolitis Obliterans Syndrome Market Size and Forecast 2025–2032 The Bronchiolitis Obliterans Syndrome Market is poised for steady expansion, driven by novel therapies and diagnostic breakthroughs. As demand rises globally, key stakeholders are reshaping market dynamics through targeted R&D and strategic collaborations, reflecting the industry’s growing scope and evolving market trends. Market Size and Overview The bronchiolitis obliterans syndrome market is estimated to be valued at USD 63.0 Mn in 2025 and is expected to reach USD 84.6 Mn by 2032, growing at a compound annual growth rate (CAGR) of 4.3% from 2025 to 2032. This market report highlights robust business growth driven by rising incidence post-lung transplant and increased awareness of long-term pulmonary sequelae. The forecast underscores expanding market revenue streams from specialty inhaled formulations and emerging biomarker-based diagnostics, indicating strong market opportunities amid evolving market drivers and restraints. Use Case Scenarios • Post-Transplant Early Detection: In Q4 2024, a US transplant center integrated a novel exhaled breath biomarker panel, cutting diagnosis lead time by 30% and improving survival rates—an application reflecting evolving market segments and market insights. • Remote Spirometry Management: A European home-care provider launched a telemonitoring program in mid-2025, leveraging connected spirometers to reduce hospital readmissions by 25%, demonstrating real-world market growth strategies in chronic patient management. • Occupational Health Screening: In late 2024, an aerospace manufacturer deployed periodic pulmonary function tests for workers exposed to chemical aerosols, achieving a 15% drop in undiagnosed BOS cases—illustrating market dynamics in workplace health compliance. Policy and Regulatory Impact • FDA Fast-Track Designation (2024): Accelerated review for an inhaled immunomodulator expanded market scope, encouraging innovation and boosting market revenue projections. • EU EMA Guideline Revision (2025): Updated post-transplant monitoring protocols mandated routine CT imaging, raising industry size and standardizing care across member states. • US Medicare Reimbursement Update (2024): New CPT codes for BOS diagnostics increased reimbursement rates by 20%, addressing market restraints related to cost barriers and enhancing market share for advanced diagnostics. • WHO Inclusion in Essential Diagnostics List (2025): Formal recognition of spirometry in low-resource settings, widening market opportunities and aligning with global market trends toward accessibility. Key Players • Zambon Pharma • Incyte Corporation • Genentech • GlaxoSmithKline • Altavant Sciences • Novartis • Roche • Pfizer • Sanofi • AstraZeneca • Boehringer Ingelheim • Mallinckrodt • Takeda • CSL Behring • Grifols ‣ Bronchiolitis Obliterans Syndrome Market: https://www.coherentmi.com/industry-reports/bronchiolitis-obliterans-syndrome-market